Design of a New Method of ARMS PCR for Detection of MMP-9 Promoter -1562 C/T Polymorphism
DOI:
https://doi.org/10.22100/jkh.v7i4.66Keywords:
MMP-9 polymorphism, ARMS PCR.Abstract
Introduction: Type IV collagens is one of the most important genes which due to its function in collagen digestion can be affective in separation of the cells from the basal lamina and the metastasis of them so this gene is known as a tumor marker of several cancers. Existence of a single nucleotide polymorphism -1562 C/T at this gene’s promoter case leads to over expression of this gene in transcription level by decreasing inhibitor protein bonding on T alleles. The aim of the present study was to investigate a new method for the person’s genotype on this polymorphism without the use of PCR_RFLP.
Methods: Using EPD genome database, the sequences of the intended region were received and by using PRIMER1 software 4 primers were designed for the area. With multiple PCR reaction, two pairs of the best primers were selected and the ARMS PCR was optimized for them. The PCR genotyping results were approved by direct Sequencing.
Results: With the use of the newly designed primers, the ARMS PCR product with 205 nucleotide size showed C allele and the PCR products with 253 nucleotide sizes showed the T allele.
Conclusions: With the use of this technique, we can determine the person’s genotype with an ARMS PCR without the use of RFLP and with a higher speed and accuracy.
References
Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases; implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999;77:465-480.
Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinase in metastasis. Journal of the National Cancer Institue 2005;89:1260-1270.
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
Pryzybylowska K, Kluuczna A, Zadrozny M. Polymorphisms of the promoter regions of matrix metalloproteinase genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Research 2006;95:65-72.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
Ozalp HM, Tanir OT, Yalcin S. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 2003;24:417-420.
Simon C, Simon M, Vucelic G. The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Experimental Cell Research 2001;271:344-355.
Chandrasekar B, Mummidi S, Mahimainathan LN. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006;281(22):15099-15109.
Ogawa K, Chen H, Kuang C. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-β is mediated by a nuclear factor-κB site. Biochem J 2004;381(2):413-422.
Zhang B, Ye S, Hermann SM. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-794.
Hemati S, Sadeghi M, Motovali Bashi M, Sahebi A, Malekshahi ZV. Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T ALLELE. Jounal of Biological Reseach 2010;13:113-118.[Persian].
Sadeghi M, Motovali Bashi M, Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. International Journal of Integrative Biology 2009;6(1):33-37.[Persian].
Miller SA, Dybes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
Liotta LA, Tryggvason K, Garbisa V, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-797.
Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T. Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 1994;58:582-586.
Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-168.
Rao JS, Steck PA, Mohanam S, Stetler- Stevenson WG, Liotta LA, Sawaya R. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993;53:2208-2211.
Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cance r-derived cell lines in vitro. Cancer Res 1996;56:3359-3365.
Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-3119.
Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001;29:E88.
Okayama N, Fujimura K, Nakamura J, Suehiro Y, Hamanaka Y, Hinoda Y. Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system polymerase chain reaction. Clin Chem Lab Med 2004;42:13-6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
